Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study - Wikidata - awgldk - TriplyDB

Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study

Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study

http://www.wikidata.org/entity/Q34593276

about

Molecular prognostic factors in cytogenetically normal acute myeloid leukemia Progress in acute myeloid leukemia MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy.Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies Molecular therapy for acute myeloid leukaemia.NF1 inactivation in adult acute myelogenous leukemia The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis.Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS.Gene mutations and molecularly targeted therapies in acute myeloid leukemia.Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner.Death pathways triggered by activated Ras in cancer cells Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance.Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation The Globalization of Cooperative Groups.Targeting oncogenic Ras signaling in hematologic malignancies.Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype.Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents.Human BDH2, an anti-apoptosis factor, is a novel poor prognostic factor for de novo cytogenetically normal acute myeloid leukemia.Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.New agents for AML and MDS.Pharmacogenomics in acute myeloid leukemia.High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade.Older patients with acute myeloid leukemia.Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics.High-dose cytarabine (HD araC) in the treatment of leukemias: a review.Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use.The use of molecular genetics to refine prognosis in acute myeloid leukemia.Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia.Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy.Prevalence and Prognostic Value of IDH1 R132 Mutation in Newly Diagnosed AML Egyptian Patients with Normal Karyotype.Higher lipocalin 2 expression may represent an independent favorable prognostic factor in cytogenetically normal acute myeloid leukemia.Association between DCK 35708 T>C variation and clinical outcomes of acute myeloid leukemia in South Chinese patients.Impact of molecular prognostic factors in cytogenetically normal acute myeloid leukemia at diagnosis and relapse.Emerging molecular predictive and prognostic factors in acute myeloid leukemia.

P2860

Q26998811-4FFBC9FE-C828-4320-893E-D98442D5547A Q27024006-E00E3366-00C3-4901-A3BC-B23C68FE7E95 Q31012806-C777845F-B1C5-4238-97E0-EE1F42820BE4 Q33515031-26E9B15A-8B73-4022-96F4-40C5C3A16EA0 Q33555627-DF3C2D51-D41F-406C-B2B3-DC965973596E Q33558141-A87D7265-6016-4C1A-AEDB-3B459BB1C289 Q33925672-0F96D1D3-0EA4-49F6-8F11-9793E0A65250 Q34065032-FF6CE194-CDFE-4C56-929A-9231CE5C0085 Q34527239-C6470C3A-9880-4BAA-922A-CF857AA6412C Q34612654-422F9C53-9B1F-43A3-A3D5-4E1277314F8E Q34638143-939F960E-720E-44EC-B420-BAF0B158F151 Q34647741-8DA42C3D-B296-4DC0-8979-3DDD973CD45A Q34709391-CB3D6936-8052-4622-B78A-B960EB8FCB84 Q34994888-E7CDC35B-BF7C-4738-A4AA-B3346E0DEA33 Q35062514-6F329480-4092-4741-A382-DD6B46E74FF9 Q35237394-3B38693C-0B1D-4D11-84AE-3BB06685FE96 Q35527456-A5FC4CAD-5D24-4E80-95F2-57A45BA4255A Q36119749-1D959330-54DA-46F7-A9EC-E6B87704C310 Q36352506-327B00CB-CFAE-43A9-BA0A-49013E3AFFE0 Q36808186-6F8D21A6-D8CA-4341-9C35-5E6C92761806 Q36926120-4E7C12AE-E65B-4066-B8BA-BDD36E39D816 Q36997966-A52E83AD-2B34-4F0D-8EFE-59BF66139A5A Q37351908-8E072406-6898-4203-9991-5DEAA8F98A3A Q37449058-A6BA5759-6A6A-4EFB-AE02-A351476936AE Q37474602-085F326A-9B91-4596-A382-07E876113DA0 Q37627876-0E5FC642-7CF9-41CD-A43D-F44B97D18866 Q37635287-B43CF053-83C1-4612-816C-7A9A758744B6 Q37810969-5EFE3B2E-584B-4329-9BBD-13E8C2FE4154 Q37954583-A3F1F638-405C-40BD-AAB1-9423817E30C1 Q38105942-DB22B3FE-E219-42BB-9F17-F459ECF6C508 Q38183943-8C967D2F-79DD-413E-9A91-B7BEBB92AF53 Q38198569-49DDB239-80E1-4A40-B811-96BF22E1182D Q38227885-19738A78-46CE-4D98-BF33-D0975A1EF01A Q38633437-2FB3416A-854D-4D07-BB52-DA00689CFFA2 Q38694866-08274C20-C548-4ABF-91AF-075B8D3D7DEE Q38963204-B76341BF-81E2-49E5-8BA8-3CBD532E6D7A Q39245039-492EAE83-8F83-420C-936F-D6DFEC9E61E7 Q39467256-9E050487-1DB3-4536-AF7B-F2C0A8D8569A Q42724137-475FAC23-BEBD-4BBC-B2E8-FCEC38731D34 Q47670541-12669AA6-451D-4DBE-BFB6-6E62D0F50384

P2860

Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study

http://www.wikidata.org/entity/Q34593276

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Patients with acute myeloid le ...... cer and Leukemia Group B study

@ast

Patients with acute myeloid le ...... cer and Leukemia Group B study

@en

Patients with acute myeloid le ...... cer and Leukemia Group B study

@nl

type

label

Patients with acute myeloid le ...... cer and Leukemia Group B study

@ast

Patients with acute myeloid le ...... cer and Leukemia Group B study

@en

Patients with acute myeloid le ...... cer and Leukemia Group B study

@nl

prefLabel

Patients with acute myeloid le ...... cer and Leukemia Group B study

@ast

Patients with acute myeloid le ...... cer and Leukemia Group B study

@en

Patients with acute myeloid le ...... cer and Leukemia Group B study

@nl

P1433

Q34593276-2D3FF983-6F4C-43B2-BAC7-C30305987D39

P1476

Q34593276-6F62C937-B9DD-4032-8BFF-A9C7E1752B15

P2093

Q34593276-0AA624E6-0E61-486A-89E9-26F38A810E10

Q34593276-2CEA2683-A8C8-469D-98CA-78CED463E179

Q34593276-D6A75C48-4012-4FB3-8618-88E9CE1ED10D

Q34593276-E2DAD367-540A-4EE6-AC08-27C2EDFA8C79

Q34593276-E9A00021-0690-4C8A-9ADB-96BA83D6A8E6

Q34593276-F08B6692-E495-4695-A969-E4D1552A1A00

P2860

Q34593276-0BACEBE9-139E-4FA9-A82C-ADBB9CD8F241

Q34593276-0E4ED79D-12AA-4792-86F0-B182FFC25049

Q34593276-17B76043-1C3B-43E3-AA58-0C5B9DBC2E43

Q34593276-183A26CA-6730-43EE-BB6B-DAAAD608D938

Q34593276-1BDEDB16-94FC-4869-A4CB-6AADB5A09CE0

Q34593276-1DFA9E60-588D-4A16-AA7F-E99042502CD7

Q34593276-348BEA45-1237-490B-8A40-1C2BAAEB045E

Q34593276-4B6FB214-326F-4B45-8FE9-416ABBDECA5E

Q34593276-4DF31067-AAF5-436B-8AD5-DDA6A43D8C20

Q34593276-5FBDA256-0354-4911-B1D3-4D1A2436D118

P304

Q34593276-C6FC26B7-8423-49E8-9B2B-2D7D89CE4997

P31

Q34593276-1E8CD3CC-34D1-4876-82B2-A4824FC1BF27

P356

Q34593276-91201C1B-742E-40FB-9BA4-2F39F800B1EC

P407

Q34593276-DC081383-484D-4F21-B823-F2CF7BDAB8EC

P433

Q34593276-3D4FB5A9-17AA-4E70-911D-EEBF3C92C128

P478

Q34593276-C5D263D6-D82D-4C99-AED3-8D1BA4B7C79A

P50

Q34593276-02C22E2A-CA6E-4EC1-9EB3-EB4BCE817DE5

Q34593276-79C05894-6137-4E19-85C7-95F69E8AC9D3

Q34593276-932C9C8C-921F-4F27-9652-6F63E67A8449

Q34593276-DA116BAF-4FED-4132-8A98-E5EA75AFA1A0

P577

Q34593276-4B6F5B57-8511-4557-B75C-82499F18363D

P698

Q34593276-7479EB06-77B0-4BF2-852E-FEBEA1DECFBA

P921

Q34593276-23ED9DC6-CD6B-4A55-BCBB-BB0285A7C107

Q34593276-C5D3FE48-C03B-42F7-9DB7-347AD4D96139

P932

Q34593276-22886DC0-A39F-458D-B84E-6B874219286C

P356

JCO.2007.14.0418

P1433

Journal of Clinical Oncology

P1476

Patients with acute myeloid le ...... cer and Leukemia Group B study

@en

P2093

Andreas Neubauer

http://www.w3.org/2001/XMLSchema#string

Christian Thiede

http://www.w3.org/2001/XMLSchema#string

Edison T Liu

http://www.w3.org/2001/XMLSchema#string

Peter Paschka

http://www.w3.org/2001/XMLSchema#string

Richard A Larson

http://www.w3.org/2001/XMLSchema#string

Robert J Mayer

http://www.w3.org/2001/XMLSchema#string

P2860

RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.

Implications of NRAS mutations in AML: a study of 2502 patients.

Targeting RAS signalling pathways in cancer therapy

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

ras oncogenes in human cancer: a review

Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication

Cisplatin, cytarabine, caffeine, and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic carcinoma: a phase II study.

Comprehensive genotypic analysis of leukemia: clinical and therapeutic implications.

Pathogenesis of acute myeloid leukaemia and inv(16)(p13;q22): a paradigm for understanding leukaemogenesis?

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

P304

4603-4609

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.14.0418

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Clara D. Bloomfield

Krzysztof Mrózek

P577

2008-06-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18559876

http://www.w3.org/2001/XMLSchema#string

P921

P932

2653132

http://www.w3.org/2001/XMLSchema#string